IN THE NEWS

Ritedose news
and updates.

Learn more about Ritedose and the community.
Press releases, news stories, partnerships, community events, and more.

Media Inquiries

Schedule your interview and learn more about the Ritedose Company.

Alex Keown

media@ritedose.com

6August2026

Hidden Contamination: What Preservative-Free Ophthalmic Patients Need to Know

Learn how Blow-Fill-Seal manufacturing supports ophthalmic sterility and why proper handling of single-use ophthalmic products is essential to preventing microbial contamination.

Ophthalmic sterility supported through Blow-Fill-Seal manufacturing at Ritedose

29July2026

Why Reclosing a Single-Use Ophthalmic Vial Doesn’t Restore Sterility

A vial may look protected after being closed again, but sterility cannot be restored once a single-use ophthalmic vial has been opened.

11June2026

Ritedose Commits to National “Hope Alliance” Campaign to Support Uninsured Patients

The leader in unit dose sterile medications pledges to the Dispensary of Hope a long-term supply of critical respiratory medications to stabilize care for vulnerable populations.

Dispensary of Hope patient story highlights Ritedose support for uninsured patients

22May2026

Purpose at Scale: What “Driven by Purpose” Looks Like in Pharmaceutical Manufacturing

Ritedose explores how purpose-driven pharmaceutical manufacturing strengthens quality, innovation and patient-centered care.

Ritedose pharmaceutical manufacturing team focused on purpose-driven innovation

12May2026

Eyedrop recall underscores need for quality focus

An FDA eye drop recall involving sterility concerns highlights the critical role of cGMP compliance, aseptic processing, and Blow-Fill-Seal technology in safe ophthalmic drug manufacturing.

Close-up of human eye with text overlay that reads, "Paramount safety: proven sterility."

7May2026

Why Pharmaceutical Resilience Is Critical in Drug Manufacturing

Pharmaceutical resilience is essential to strengthening the U.S. drug supply chain against shortages, global dependencies, and emerging risks.

Pharmaceutical resilience in U.S. drug manufacturing and supply chain

28April2026

Ritedose Reaches “1,000 Hours of Purpose”

Employee-led initiative deepens Ritedose’s commitment to Midlands nonprofits and the communities they serve.

Ritedose community service volunteers supporting Midlands nonprofits

23April2026

Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing

– Collaboration showcases the Ritedose Center of Excellence as a global hub for advanced manufacturing education. – The Center of Excellence serves as a cornerstone of Ritedose’s broader commitment to workforce development and industry leadership.

ESCP Business School students visiting Ritedose Manufacturing Center of Excellence at University of South Carolina partnership event

10April2026

What Does it Mean to be a Manufacturer of Choice?

Ritedose explains how quality, reliability, and Blow-Fill-Seal (BFS) expertise define what it means to be a true manufacturer of choice in pharmaceutical manufacturing.

Manufacturer of Choice pharmaceutical manufacturing at Ritedose

8April2026

Ritedose Announces Manufacturing for Tenpoint Therapeutics’ Presbyopia Eye Drop

Partnership Signals Commercial Readiness and Manufacturing Strength for Groundbreaking Ophthalmic Treatment.

Ritedose presbyopia eye drop manufacturing

27March2026

Meeting Patient Needs Through Flexible Pharmaceutical Manufacturing

Pharmaceutical manufacturing at scale requires flexibility, cGMP compliance and advanced technology to ensure safe, reliable medications for patients.

Pharmaceutical Manufacturing facility producing sterile medications using Blow-Fill-Seal technology

13March2026

Blow-Fill-Seal: How Ritedose Is Setting the Standard in Pharmaceutical Manufacturing

Blow-Fill-Seal manufacturing is transforming sterile pharmaceutical production, and Ritedose is setting the standard through innovation, quality systems and scalable CDMO expertise.

Blow-Fill-Seal pharmaceutical manufacturing at Ritedose

27February2026

How Ritedose Addresses Drug Shortages

Ritedose helps address drug shortages by using advanced sterile manufacturing and strategic partnerships to keep essential treatments available.

Ritedose sterile pharmaceutical manufacturing addressing drug shortages.

20February2026

Ritedose Honored With SCbio’s 2026 Life Sciences Pinnacle Award for Organizational Contribution

South Carolina’s largest sterile CDMO recognized for visionary leadership, innovation, and community impact at SCbio’s annual Life + Science Conference.

Pinnacle Award for Organizational Contribution | Jody Chastain CEO of Ritedose accepting Pinnacle Award at SCbio Life Sciences Conference 2026

11February2026

South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub

Ritedose is helping shape a new era of innovation in South Carolina, where life sciences companies are scaling faster than ever before.

South Carolina Life Sciences innovation led by Ritedose manufacturing expansion

30January2026

Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US

This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.

Ritedose Blow-Fill-Seal Technology | Aerial view of Ritedose pharmaceutical manufacturing facilities in Columbia, South Carolina, showcasing the largest U.S. Blow-Fill-Seal CDMO.

16January2026

How Ritedose Supports a Stable and Reliable Medication Supply

Learn how Ritedose safeguards patients’ access to critical medications with responsive, high-quality pharmaceutical manufacturing.

Automated pharmaceutical warehouse with a yellow robotic arm stacking cardboard boxes, illustrating Ritedose’s focus on transparency, efficiency, and solutions for drug shortages.

23December2025

Ritedose 2025 Year-In-Review

Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.

18November2025

A Season of Gratitude and Purpose: A Thanksgiving Message from Jody Chastain, CEO of Ritedose

Ritedose has been built on the generosity, mentorship, and support of countless individuals and organizations across South Carolina. And with that good fortune comes a responsibility to give back to our patients, our people, and our community.

29October2025

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic…

FEATURED NEWS

6th August 2026

Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing

10th April 2026

RECEIVE THE LATEST NEWS

Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.

Ritedose news
and updates.

Media Inquiries

Alex Keown

media@ritedose.com

Hidden Contamination: What Preservative-Free Ophthalmic Patients Need to Know

Why Reclosing a Single-Use Ophthalmic Vial Doesn’t Restore Sterility

Ritedose Commits to National “Hope Alliance” Campaign to Support Uninsured Patients

Purpose at Scale: What “Driven by Purpose” Looks Like in Pharmaceutical Manufacturing

Eyedrop recall underscores need for quality focus

Why Pharmaceutical Resilience Is Critical in Drug Manufacturing

Ritedose Reaches “1,000 Hours of Purpose”

Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing

What Does it Mean to be a Manufacturer of Choice?

Ritedose Announces Manufacturing for Tenpoint Therapeutics’ Presbyopia Eye Drop

Meeting Patient Needs Through Flexible Pharmaceutical Manufacturing

Blow-Fill-Seal: How Ritedose Is Setting the Standard in Pharmaceutical Manufacturing

How Ritedose Addresses Drug Shortages

Ritedose Honored With SCbio’s 2026 Life Sciences Pinnacle Award for Organizational Contribution

South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub

Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US

How Ritedose Supports a Stable and Reliable Medication Supply

Ritedose 2025 Year-In-Review

A Season of Gratitude and Purpose: A Thanksgiving Message from Jody Chastain, CEO of Ritedose

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

FEATURED NEWS

Hidden Contamination: What Preservative-Free Ophthalmic Patients Need to Know

Why Reclosing a Single-Use Ophthalmic Vial Doesn’t Restore Sterility

Purpose at Scale: What “Driven by Purpose” Looks Like in Pharmaceutical Manufacturing

Eyedrop recall underscores need for quality focus

Why Pharmaceutical Resilience Is Critical in Drug Manufacturing

Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing

What Does it Mean to be a Manufacturer of Choice?

Ritedose Announces Manufacturing for Tenpoint Therapeutics’ Presbyopia Eye Drop

Meeting Patient Needs Through Flexible Pharmaceutical Manufacturing

Blow-Fill-Seal: How Ritedose Is Setting the Standard in Pharmaceutical Manufacturing

RECEIVE THE LATEST NEWS

TAGS CLOUD

Quick Links

Receive the latest news.

Ritedose news and updates.

Media Inquiries

Alex Keown

FEATURED NEWS

RECEIVE THE LATEST NEWS

TAGS CLOUD

Tags

Quick Links

Receive the latest news.

Ritedose news
and updates.